BlackRock MuniYield New York Quality Fund (NYSE:MYN) versus VanEck Biotech ETF (NASDAQ:BBH) Financial Contrast

VanEck Biotech ETF (NASDAQ:BBH) and BlackRock MuniYield New York Quality Fund (NYSE:MYN) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility and Risk

VanEck Biotech ETF has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, BlackRock MuniYield New York Quality Fund has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Profitability

This table compares VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VanEck Biotech ETF	N/A	N/A	N/A
BlackRock MuniYield New York Quality Fund	N/A	N/A	N/A

Earnings & Valuation

This table compares VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VanEck Biotech ETF	N/A	N/A	N/A	N/A	N/A
BlackRock MuniYield New York Quality Fund	$19.20 million	20.27	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VanEck Biotech ETF	0	4	2	0	2.65
BlackRock MuniYield New York Quality Fund	0	0	0	0	0.00

VanEck Biotech ETF presently has a consensus target price of $158.52, suggesting a potential upside of 0.00%. Given VanEck Biotech ETF’s stronger consensus rating and higher probable upside, research analysts clearly believe VanEck Biotech ETF is more favorable than BlackRock MuniYield New York Quality Fund.

Insider and Institutional Ownership

32.0% of VanEck Biotech ETF shares are owned by institutional investors. Comparatively, 29.3% of BlackRock MuniYield New York Quality Fund shares are owned by institutional investors. 1.0% of BlackRock MuniYield New York Quality Fund shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

VanEck Biotech ETF pays an annual dividend of $1.25 per share and has a dividend yield of 0.8%. BlackRock MuniYield New York Quality Fund pays an annual dividend of $0.54 per share and has a dividend yield of 5.3%.

Summary

VanEck Biotech ETF beats BlackRock MuniYield New York Quality Fund on 5 of the 8 factors compared between the two stocks.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

About BlackRock MuniYield New York Quality Fund

BlackRock MuniYield New York Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in a portfolio of long-term investment grade municipal bonds exempt from federal income taxes and New York State and New York City personal income taxes. BlackRock MuniYield New York Quality Fund, Inc was formed on March 16, 1992 and is domiciled in United States.